Dr. Boris Heifets's research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. They bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.